Charting plays much less of a roll, in predicting stock performance, in the area of oil stocks, which, right or wrong, closely follow the per barrel price of oil.
GILD and ISCO are not an apples to apples comparison company history wise, but you do make a good point.
I guess the MM's went to lunch :) there was more than an hour with no recorded trades, then suddenly it started up agai at the normal rate of 3-4 trades a minute. I got no idea why
Unregistered Sale of Equity Securities
ITEM 3.02 Unregistered Sales of Equity Securities
International Stem Cell Corporation filed its Annual Report on Form 10-K (the "2014 Annual Report") on March 30, 2015 reporting 252,011,924 shares outstanding as of March 25, 2015.
From March 26, 2015 through April 22, 2015, the Company has issued an additional 13,722,045 shares of common stock in transactions that were not registered under the Securities Act of 1933, with the issuances on April 22, 2015 resulting in an increase in the number of shares of common stock outstanding by more than 5% compared to the number of shares last updated in the 2014 Annual Report. The Company has issued a total of 5,966,500 shares of common stock to holders of its Series H-1 Convertible Preferred Stock upon conversion of a portion of the shares of Series H-1 Convertible Preferred Stock. The shares of common stock issued upon conversion of shares of Series H-1 Convertible Preferred Stock were issued in reliance upon the exemption from registration in Section 3(a)(9) of the Securities Act of 1933. In addition, the Company issued 1,861,331 shares to Dr. Ruslan Semechkin upon the exercise for cash of his Series C Warrants and 5,894,214 shares to Dr. Andrey Semechkin upon the exercise for cash of his Series C Warrants. The Series C Warrants were issued in the financing transaction completed in October 2014. The Company received total consideration of $347,000 upon exercise of those warrants. The shares of common stock issued upon exercise of those warrants were offered and sold in a private placement transaction in reliance upon the exemption from registration in Section 4(a)(2) of the Securities Act of 1933. Dr. Andrey Semechkin is the Company's Chief Executive Officer and Co-Chairman of the Board, and Dr. Ruslan Semechkin is the Company's Chief Scientific Officer and a Director. Reflecting these issuances, as of April 22, 2015, the Company had 265,733,969 shares of common st
Well written and right on the money. This is the time to grab some shares. Anything under $2.00 is a steal. Those folks who gobbled up shares from the over allotment option, have a better idea of what is coming than the bashers on this thread.
It is early in the study but the results seem impressive on the stroke issue. Whether a buy out or just a partner with money, come down the road, is certainly a possibility. We don't know enough about all the facts of the various issues but rest assured, there are experts looking closely at the current results. It certainly is a "gambling stock" I wouldn't bet the rent money. However, the potential is there, in my opinion, to make it worth latching on to some shares. You also have, with this type of stock, the possibility of a sudden upswing, do to national publicity. NBC Nightly news often reports on studies of interest, involving small companies. If they were to mention the stroke study and early findings, along with a company name, the stock would take off for a few days, allowing for some short term gains. Yes, the company is in bad financial shape, yes there is dilution, that's why it's a 5 cent stock. Those issues are pretty well built into the price and not unusual. It is a speculative stock with no guarantee of any type. If you are a bit of a gambler at heart, it might just be worth an try :)
Trashing the stock......Not sure what his "thing" is but it would be interesting to know his motivations. To save all us poor souls from loosing money? I doubt it.....:)
Law suits are a dime a dozen these days, FDA warning is a minor advisory notice, easily correctable. The company has a huge forward potential. Hide under your rock and watch :)
Yep, but the same could be said about ACTC now OCAT. I bought their stock many years back. Got in around .02 at one point had 200,000 shares. I jumped off with a very nice profit, when it hit .25. At one point the Nay Sayers were carrying on, just like you are. They didn't have enough cash to pay the power bill. Today they are a $6.00 stock on the NASDAQ. It's a gamble for sure. I am not yet ready to give up. They have some very likely successes ahead. If you don't think so, sell. If you are a gambler....hang in there....:)
Agreed and when you look at how the underwriters snapped up the shelf offering, there has to be something good about the company. They now have adequate funds to go forward and it appears a bottom is in place for now. A ton of crap has been spewed about the company but it appears the basic facts are present to move ahead. A good investment at this price.
Being in financial trouble and share dilution is par for the course with research companies. Not yet time to panic. Predicting that this type of company might have financial/dilution problems doesn't take a brain child. The point is, they are on their way to something big. When they get there, those who "stuck with it" will be rewarded. Is it a gamble? Of course it is.......perhaps one with a big payout. Don't bet the grocery money but if you have a few extra bucks.it might just be worth it.:)